Biopharma giant Biogen and RNA-targeted therapy leader Ionis Pharmaceuticals announced topline results from their Phase I study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide for people with a specific type of amyotrophic lateral sclerosis (ALS).
One year after Astellas and California-based Cytokinetics extended an agreement to develop Skeletal Sarcomere Activators, the Japanese pharma company is walking away from the deal.
Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.
A pro-regenerative cell discovered by researchers at Ohio State and the University of Michigan could open the door to potentially groundbreaking immunotherapeutic treatments for diseases such as ALS and multiple sclerosis.
With $29 million in the company’s pocket, biotech Libra Therapeutics launched to take on neurodegenerative disease, with three pre-clinical programs ready to roll.
Cambridge, Massachusetts-based Yumanity Therapeutics and Boston-based Proteostasis Therapeutics announced plans to merge. The combined company will operate after the deal as Yumanity Therapeutics, and will focus on protein misfolding and neurodegenerative diseases.
We now have technology to help us keep track of mundane – but crucial – tasks. From wearables to smartphones, we have unlimited opportunities to make technology work for us.